Uphononongo lweklinikhi luyilelwe ukuvavanya ukhuseleko kunye nokusebenza kakuhle kwe-LNK01001 kwizifundo ezine-arthritis esebenzayo ephakathi ukuya kwi-rheumatoid enempendulo engafanelekanga okanye yokunganyamezeli amayeza aqhelekileyo okwenziwa kwezifo ze-antirheumatic (csDMARDs).
I-LNK01001 iyona mayeza okuqala aphuhliswe yi-Lynk Pharmaceuticals, kwaye i-kinase inhibitor ekhethiweyo yonyango lwezifo ezizimele. Ngaphambili, i-LNK01001 yagqiba izifundo zeklinikhi zeSigaba soku-I kwizifundo eziphilileyo ngehlobo lalo nyaka e-China nase-Australia nase-Japan, ixhaswa yi-Lynk Pharmaceuticals kunye neqabane layo lase-US, ngokulandelelanayo. Iziphumo zibonise ukuba iyeza likhuselekile kwaye linyamezeleke kakuhle. Ukongezelela, i-LNK01001 yavunywa yi-National Medical Products Administration yaseChina (NMPA) yovavanyo lweklinikhi yezibonakaliso ezintsha - i-ankylosing spondylitis (AS) kunye ne-atopic dermatitis (AD).
Unjingalwazi uXiaofeng Zeng ungumphenyi oyintloko wolu phando kunye nomlawuli weSebe leRheumatology kunye ne-Immunology yeSibhedlele sasePeking Union Medical College kunye neChina Academy yeSayensi yezoNyango.
INTO ONOKUYITHATHA KWELI NQAKU:
- Previously, LNK01001 completed Phase I clinical studies in healthy subjects in the summer of this year in China and in Australia and Japan, sponsored by Lynk Pharmaceuticals and its US partner, respectively.
- Unjingalwazi uXiaofeng Zeng ungumphenyi oyintloko wolu phando kunye nomlawuli weSebe leRheumatology kunye ne-Immunology yeSibhedlele sasePeking Union Medical College kunye neChina Academy yeSayensi yezoNyango.
- Uphononongo lweklinikhi luyilelwe ukuvavanya ukhuseleko kunye nokusebenza kakuhle kwe-LNK01001 kwizifundo ezine-arthritis esebenzayo ephakathi ukuya kwi-rheumatoid enempendulo engafanelekanga okanye yokunganyamezeli amayeza aqhelekileyo okwenziwa kwezifo ze-antirheumatic (csDMARDs).
